Search Results for "durvalumab experience"

A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Apr 20^th • 7 mins read

Fei Liang, Sheng Zhang, Qin Wang, Wenfeng Li

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

Aug 31^st • 16 mins read

Mateusz T. Wasylewski, Karolina Strzebonska, Magdalena Koperny, Maciej Polak, Jonathan Kimmelman, Marcin Waligora

Clinical development success rates and social value of pediatric Phase 1 trials in oncology

Jun 21^st • 28 mins read

Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

May 21^st • 8 mins read

Carrie Printz

Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps

Jan 9^th • 2 mins read

Jonathan H. Cheng, Justin W. Tiulim, Sheng Zhou, Anthony El-Khoueiry and Jorge Nieva

Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials

Oct 18^th • 10 mins read

S.E. Abdullah, E. Oflazoglu, J.C. Soria, M.M. Dar

New Realities of Phase I Clinical Trials in the Era of

Oct 7^th • 5 mins read

Louis Everest, BSc; Monica Shah, BSc; Kelvin K.W. Chan, MD, MSc, PhD

Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale

Jul 10^th • 12 mins read

Envision Pharma Group

Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 9^th • 5 mins read

Shen Lin, Yaping Huang, Liangliang Dong, Meiyue Li, Yahong Wang, Dian Gu, Wei Wu, Dongni Nian, Shaohong Luo, Xiaoting Huang, Xiongwei Xu and Xiuhua Weng

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

Feb 23^rd • 9 mins read

Mahnum Shahzad, BA, Huseyin Naci, MHS, PhD, Anita K. Wagner, PharmD, MPH, DrPH

Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated

Oct 18^th • 5 mins read

Meena N Murugappan, PharmD, MPH, PhD(c), Bellinda L King-Kallimanis, PhD, Gregory H Reaman, MD, Vishal Bhatnagar, MD, Erica G Horodniceanu, MPH, Najat Bouchkouj, MD, Paul G Kluetz, MD

Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective

Apr 30^th • 12 mins read